Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2017
Should value frameworks take a ‘societal perspective’?
6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...
Posted by Michael Wonder on 09 Sep 2017
Can a new value framework help ease friction over orphan drug prices?
7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...
Posted by Michael Wonder on 31 Aug 2017
Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications
30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three ...
Posted by Michael Wonder on 15 Aug 2017
Institute for Clinical and Economic Review releases draft evidence report on cognitive and mind-body therapies for treatment of chronic low back and neck pain
15 August 2017 - Public comment period now open until 12 September; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 12 Aug 2017
Institute for Clinical and Economic Review to evaluate comparative clinical effectiveness and value of emicizumab for haemophilia A
11 August 2017 - Open input period now open until 6 September 2017. ...
Posted by Michael Wonder on 09 Aug 2017
Institute for Clinical and Economic Review posts draft scoping document on CAR-T therapies for public comment
9 August 2017 - Report expected to review axicabtagene ciloleucel and tisagenlecleucel-t, first CAR-T therapies submitted for FDA. ...
Posted by Michael Wonder on 26 Jul 2017
Institute for Clinical and Economic Review announces potential topics for review in 2018
26 July 2017 - Tentative list includes drugs for migraines, haemophilia, and cystic fibrosis. ...
Posted by Michael Wonder on 25 Jul 2017
Dr Steve Pearson on using health technology assessment to guide decision making
23 July 2017 - Health technology assessment is a tool that helps to objectively evaluate evidence, which levels the playing field ...
Posted by Michael Wonder on 25 Jul 2017
ICER seeks public comment on proposed value assessment framework for treatments that represent a potential major advance for serious ultra-rare conditions
25 July 2017 - ICER’s fundamental approach to value assessment remains constant with proposed changes for special circumstances. ...
Posted by Michael Wonder on 19 Jul 2017
Institute for Clinical and Economic Review to evaluate CAR-T therapies in upcoming report
19 July 2017 - Report tentatively expected to review axicabtagene ciloleucel (Kite Pharmaceuticals) and tisagenlecleucel-t (Novartis). ...
Posted by Michael Wonder on 17 Jul 2017
Institute for Clinical and Economic Review's final evidence report finds prices of anabolic agents for osteoporosis too high, not aligned with potential benefits over other treatments
17 July 2017 - Policy recommendations highlight need for prices to align with clinical benefit, clear guidelines to define highest ...
Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 11 Jul 2017
Institute for Clinical and Economic Review posts draft scoping document on voretigene neparvovec, first gene therapy submitted for FDA approval
10 July 2017 - Report expected to review clinical effectiveness, value of the therapy; Scoping Document will be open to ...
Posted by Michael Wonder on 28 Jun 2017
ICER evidence report on abuse deterrent opioids finds limited evidence to demonstrate real world impact on opioid abuse
28 June 2017 - With substantially higher costs for abuse-deterrent formulations, and uncertainty regarding their impact on abuse, diversion, and switching ...
Posted by Michael Wonder on 27 Jun 2017
The Institute for Clinical and Economic Review to collaborate with the Department of Veterans Affairs' Pharmacy Benefits Management Services Office
27 June 2017 - ICER drug assessment reports to support VA drug coverage and price negotiation with pharmaceutical companies to ...